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Summary
Objective: The effect of the prostaglandin E2 (PGE2) signal through prostaglandin E receptor 2 (EP2) receptors on the repair of injured
articular cartilage was investigated using a selective agonist for EP2.
Methods: Chondral and osteochondral defects were prepared on the rabbit femoral concave in both knee joints, and gelatin containing poly-
lactic-co-glycolic acid microspheres conjugated with or without the EP2 agonist was placed nearby. Animals were sacriﬁced at 4 or 12 weeks
post-operation, and regenerated cartilage tissues and subchondral structure remodeling were evaluated by histological scoring. The quality of
regenerated tissues was also evaluated by the immunohistochemical staining of EP2, type II collagen, and proliferating cell nuclear antigen
(PCNA). As an evaluation of side effects, the inﬂammatory reaction of the synovial membrane was analyzed based on histology and the
mRNA expression of matrix metalloproteinase3 (MMP3), tissue inhibitor of metalloproteinase 3 (TIMP3), and interleukin-1b (IL-1b). Also,
the activity of MMP3 and the amount of tumor necrosis factor-a (TNF-a) and C-reactive protein in joint ﬂuid were measured.
Results: In both models, the EP2 agonist enhanced the regeneration of the type II collagen-positive tissues containing EP2- and PCNA-pos-
itive chondrocytes, and the histological scale of regenerated tissue and subchondral bone was better than that of on the control side, partic-
ularly at 12 weeks post-operation. No inﬂammatory reaction in the synovial membrane was observed, and no induction of pro-inﬂammatory
cytokines was found in joint ﬂuid.
Conclusion: Selective stimulation of the PGE2 signal through EP2 receptors by a speciﬁc agonist promoted regeneration of cartilage tissues
with a physiological osteochondral boundary, suggesting the potential usefulness of this small molecule for the treatment of injured articular
cartilages.
ª 2008 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Chondrocytes in articular cartilage are differentiated cells
with minimum proliferating potential and low metabolic
activity1. Because these cells are fully responsible for the
production of cartilage matrix consisting of collagens and
proteoglycans, considerable damage to articular cartilage
is unrepairable, initiating a sequence of catabolic events
leading to a pathological condition known as osteoarthritis
(OA). Although inﬂammation of the synovium and the de-
struction of subchondral bone integrity also play an impor-
tant role in the progression of OA, the poor regenerative
capacity of chondrocytes is the major disease-causing fac-
tor1,2. In the early stages of OA, however, not only catabolic*Address correspondence and reprint requests to: Dr T. Aoyama,
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529but also anabolic activity is enhanced in chondrocytes. As
catabolic activity, chondrocytes produce several catabolic
cytokines such as interleukin-1 (IL-1), which in turn induce
the production of proteinases such as matrix metalloprotei-
nases (MMPs) and a disintegrin-like and metalloprotease
with thrombospondin (ADAMTS) leading to the destruction
of the matrix network2. As anabolic activity, chondrocytes
produce anabolic cytokines such as the bone morphogenic
protein (BMP) family and insulin like growth factor-1 (IGF-1),
which induce the synthesis of collagens and initiate the pro-
liferation of chondrocytes themselves making osteophytes
at the periphery2. A disruption of the equilibrium between
the catabolic and anabolic activities results in catastrophic
damage to articular cartilage. In adult articular cartilage,
the equilibrium leans toward catabolic activity; the prolifera-
tion of chondrocytes is decreased and the subchondral
structure is weak.
The role of prostaglandin E2 (PGE2) in the development
of OA is controversial. Pro-inﬂammatory signal mediators
such as IL-1 and tumor necrosis factor-a (TNF-a) induce
530 S. Otsuka et al.: PGE2 signal via EP2 receptorsthe synthesis of PGE2 by promoting the expression or activ-
ities of cycloxygenase (COX)-2 and microsomal PGE
synthase-13. The synthesized PGE2 promotes IL-1 expres-
sion as a positive feedback mechanism, degrades the
cartilage matrix4, and ﬁnally induces apoptosis of chondro-
cytes5, indicating a catabolic role for PGE2 in OA. In some
reports, however, anabolic effects of PGE2 were demon-
strated1,3. PGE2 opposed the effect of IL-1 by down-
regulating type I collagen6 and stimulating type II collagen
gene expression7,8. Also, PGE2 stimulated the synthesis
of proteoglycan and collagen through the induction of
IGF-1-binding protein9, and induced the proliferation of rat
chondrocytes as demonstrated by an increase in the incor-
poration of [3H]-thymidine9.
Several factors are involved in these controversial ﬁndings
including experimental design, the level of PGE2 expression,
the balance with other pro-inﬂammatory cytokines, and most
notably, the variety of receptors. PGE2 exerts its biological
effect through one of four receptors, EP1, EP2, EP3, or
EP4. The development of speciﬁc agonists and antagonist
for each receptor enables the understanding of the recep-
tor-speciﬁc signal transduction mechanism and its conse-
quence. Signals through EP1 and EP3 coupled by Gi
protein increase the intra-cellular Ca2þ concentration, and
those through EP2 and EP4 coupled by Gs protein increase
cyclic adenosinemonophosphate (cAMP). Although the sec-
ond messenger is common, the amide acid identity is only
31% between EP2 and EP4. EP4 (513 amino acids) has
the longest intra-cellular C terminal, but EP2 (362 amino
acids) has a compact structure. In osteoclastogenesis, the
EP2 and EP4 mediate the induction of receptor activator of
nuclear factor-kappa B (NF-kB) ligand (RANKL), but the ex-
tent of the contribution by each receptor is different. Although
both EP2 and EP4 are expressed in dendritic cell, EP4 has
selective action for cell migration. This selectivity of EP4
may be caused by the fact that EP4 but not EP2 couples to
phosophatidylinositol 3-kinase in addition to cAMP10.
We have previously demonstrated that EP2 was the ma-
jor PGE2 receptor in articular chondrocytes11. And a speciﬁc
agonist for EP2 not EP4 promoted the growth of mouse and
human chondrocytes by up-regulating the expression of
growth-promoting genes such as the cyclin D gene stimulat-
ing the increase of cAMP11. The protein structure and func-
tion of EP2 are conserved between many species, and the
amino acid homology between the human and mouse, rat,
or rabbit is 88.2, 84.9, and 90.2%, respectively. The effect
of the EP2 agonist on chondrocytes was conﬁrmed in
a rat organ culture system, suggesting the possible applica-
tion of this small molecule as a new therapeutic tool for in-
jured articular cartilage11.
In this study, we investigated the effect of an EP2 agonist
on injured articular cartilage in vivo using rabbit knee joints
and also on other joint structures such as the synovium and
subchondral bone.Materials and methodsREAGENTSMicrospheres loaded with the selective EP2 agonist, ONO-8815Ly12 pre-
pared by the emulsionesolvent evaporation method as described13. Brieﬂy,
ONO-8815Ly was dissolved in puriﬁed water as the inner water phase and
polylactic-co-glycolic acid (PLGA) was dissolved in dichloromethane as the
oil phase. The water/oil (w/o) emulsion was gradually added to the outer wa-
ter phase containing polyvinyl alcohol (PVA, 0.1%, w/v), NaCl (2%, w/v) and
maltose (2%, w/v) adjusted to pH 3.0, under stirring with a turbine-shaped
mixer at 5000 rpm to obtain a water/oil/water emulsion. Then PLGA micro-
spheres were formed in the outer water phase after the evaporation of di-
chloromethane. In order to recover the microspheres without a free form ofONO-8815Ly, the suspension was centrifuged at 3000 rpm for 10 min and
the microspheres were precipitated. The washed microsphere precipital
was lyophilized to remove residual organic solvent and water, and then dried
solid ONO-8815Ly-loaded microspheres were recovered. ONO-8815Ly-
loaded microspheres were dispersed in puriﬁed water, and then gelatin
aqueous solution (20%, w/w) was poured into the microsphere suspension.
The resultant microsphereegelatin suspension was poured into a polypropyl-
ene container and placed in a refrigerator for 12 h to form a gel. Afterward,
glutaraldehyde aqueous solution (12.5 mg/ml) was poured into the micro-
sphereegelatin gel and placed in the refrigerator for 24 h for the crosslink
reaction. The gel sheet obtained was placed into glycine aqueous solution.
These procedures were performed repeatedly. Small cylinder-shaped gelatin
hydrogels containing either 80 or 400 mg of ONO-8815 were obtained by
hollowing out the gelatin hydrogel sheet.SURGICAL PROCEDUREThe institutional animal research committee, according to the guidelines
for Animal Experiments of Kyoto University, approved this investigation.
Japanese white rabbits (Shimizu Laboratory Supplies Co., Kyoto, Japan)
were at least 5 months old and had a body weight of 3 kg.
Two types of cartilage defect on the femoral concave of the patello-femoral
joint weremade according to depth (Supplementary Fig. 1). A chondral defect,
which involved the osteochondral boundary (tide mark) but not subchondral
bone, was made using a punch without damaging the subchondral bone
(5.0 mm in diameter) [Supplementary Fig. 1(AeC)]. An osteochondral defect
wasmade using a hand drill [4.0 mm in diameter and 5.0 mm in depth, Supple-
mentary Fig. 1(DeF)]. By preliminary experiments, we have conﬁrmed that
both types of defects were not healed spontaneously (data not shown).
The same type of defect was created in both femurs, and a cylinder-shaped
gelatin hydrogel containing PLGA microspheres conjugated with ONO-8815
(80 or 400 mg) was placed into the infra-patellar fat pad on one side (thereafter
designated EP2 agonist-treated samples), and gelatin hydrogels without mi-
crospheres were placed on the contralateral side (contralateral samples).
The animals were allowed to move. To exclude any possible effect of ONO-
8815 in the systemic circulation, controls were established, in which empty
gelatin hydrogel was placed in bilateral knee joints after creating each defect
model (control samples, N¼ 3). Animals were sacriﬁced and evaluated at 4
(N¼ 5) and 12 (N¼ 8) weeks after the operation.HISTOLOGICAL EVALUATIONCartilage samples were ﬁxed overnight at 4C in a 10% formalin solution,
decalciﬁed by formic acid, and embedded in parafﬁn. Then sections were cut
at 6 mm through the center of each defect, stained with Safranin-O/Fast
Green and hematoxylineeosin (HE), examined in a blinded manner by two
evaluators, and graded with the use of a modiﬁed Wakitani histological
scale14. The reconstitution of articular chondrocytes and subchondral bone
connections (category II on the modiﬁed Wakitani scale) was partially evalu-
ated by grading from 0 to 7. Specimens of the synovium around the infra-
patellar fat pads were ﬁxed in 10% formalin, embedded in parafﬁn, and cut
into 6 mm thick sections for histological evaluation. Sections were stained
with HE and the severity of synovial lesions was graded according to the
histological scoring system, based on the hyperplasia of synovial lining cells,
hypertrophy of the synovial lining layer, inﬁltration of inﬂammatory cells,
proliferation of granulation tissue, and vascularization15. Two independent
observers blinded to the treatment groups graded all sections.IMMUNOHISTOCHEMISTRYImmunostaining of proliferating cell nuclear antigen (PCNA; diluted 1:100;
Dako, Glostrup, Denmark) and alpha1 type II collagen (diluted 1:50; Daiichi
Fine Chemical, Toyama, Japan) was performed as previously mentioned11.
Immunostaining of EP2 (diluted 1:100; Cayman Chemical Co., Ann Arbor,
MI) was performed as described by Fukuda et al.16. Under the microscope
(400), all cells and PCNA-positive cells were counted by two individuals.
Three visual ﬁelds were randomly selected by each observer, and, therefore,
each specimenwas evaluated three times. Then labeling indexwas calculated
as themean of these three values. The relative increase inPCNA-positive cells
was expressed as the ratio of the labeling index of the EP2 agonist-treated
sample vs that of the contralateral sample. The labeling index of control sample
was also calculated as a value relative to those of contralateral sample.ASSAY OF MMP3, TNF-a, AND C-REACTIVE PROTEIN (CRP)
IN SYNOVIAL FLUIDAfter the injection of 1 ml of saline solution into the knee joint, synovial
ﬂuid was obtained by arthrocentesis through a sub-patellar approach.
Synovial ﬂuid was aspirated as far as possible from the knee joint. After
Fig. 1. Effects of EP2 agonist on the regeneration of chondral defects. Histological evaluations were performed at 4 (A) or 12 (C) weeks after
the operation. Each specimen was prepared from control samples (a, e, and i), contralateral (b, f, and j), or EP2 agonist-treated (c, g, and k,
80 mg/gel; d, h and l; 400 mg/gel) samples. The quality of regenerated tissues was analyzed by HE staining (aed), Safranin-O staining (eeh),
or immunohistochemical staining with anti-type II collagen Ab (iel). Magniﬁcation 2. Bar¼ 2.0 mm. The quality of regenerated tissues was
also evaluated with a modiﬁed Wakitani histological scale at 4 (B) and 12 (D) weeks after the operation. Dotted and open boxes indicate the
scale for control and contralateral samples, respectively, *P< 0.05.
531Osteoarthritis and Cartilage Vol. 17, No. 4the specimen was centrifuged at 1500 rpm for 20 min, the supernatant
was drawn out and stored at 70C17. MMP3 activity was measured
with a MMP3 ﬂuorimetric drug discovery kit (BIOMOL International LP,
Plymouth Meeting, PA). TNF-a levels in joint ﬂuids were measured using
a sandwich enzyme-linked immunosorbent assay (ELISA) with speciﬁc
anti-TNF-a polyclonal antibodies (Abs) (BD Pharmingen, San Diego,
CA). Brieﬂy, microtiter plates were coated with 50 ml of anti-rabbit. TNF-
a capture Abs (4 mg/ml) overnight at 4C, then washed twice with phos-
phate buffered saline (PBS) containing 0.05% Tween 20 and blocked
overnight at 4C with 10% fetal bovine serum (FBS) in PBS. After the
plates were washed four times, standards and samples (100 ml) were
incubated in duplicate overnight at 4C. Plates were again washed and
a biotin-conjugated anti-TNF-a secondary Ab (2 mg/ml) was added for
1 h at room temperature. A 30-min incubation with a 1:400 dilution of avi-
dineperoxidase (Sigma) followed extensive washing of the plate. Finally,Table










*All primer sequences are written from 50 to 30. The top sequence is thTMBlue (Intergen, Milford, MA) substrate was added (100 ml/well) and
incubated at room temperature for 30 min. The absorbance was read at
450 nm with an UVmax microplate reader (Molecular Devices, Menlo
Park, CA). Rabbit CRP was measured with a rabbit CRP ELISA kit (Alpha
Diagnostic International Inc., San Antonio, TX).REVERSE TRANSCRIPTION-POLYMERASE CHAIN REACTION
(RT-PCR)Total RNA was extracted from frozen synovial samples using TRIzol
reagent (Invitrogen, Carlsbad, CA) and 1 mg was reverse transcribed for
single-stranded cDNA using the oligo (dT) primer and Superscript II reverse
transcriptase (Invitrogen). RT-PCR was performed in duplicate for each
sample using primers listed in Table I18,19.I
T-PCR analyses









e sense primer and the bottom sequence is the anti-sense primer.
532 S. Otsuka et al.: PGE2 signal via EP2 receptorsQUANTITATIVE RT-PCRThe levels of mRNA expression of genes (MMP3, TIMP1, IL-1b and glyc-
eraldehyde 3-phosphate dehydrogenase (GAPDH )) were quantiﬁed by
SYBR Green (Applied Biosystems, Foster City, CA) real time PCR with the
ABI PRISM 377 Sequence Detection System (Applied Biosystems). Each
gene ampliﬁcation efﬁciency was similar with GAPDH. All reactions were
run in triplicate, and the mean value was used to calculate the ratio of target
gene/GAPDH expression in each sample. Using the ratio in untreated sam-
ple as a standard (1.0), the relative ratio of the treated sample was presented
as the relative expression level of the target gene11.STATISTICAL ANALYSESAll statistical analyses were performed using Statcel software. The results
are shown as the meanSD. The analysis of variance (ANOVA) test was
used to compare the differences in the scales between multiple groups.
The Student’s T test was used to compare the differences in the scales
between two groups. A P value< 0.05 was considered signiﬁcant.ResultsEP2 AGONIST PROMOTED TISSUE REGENERATION
IN THE CHONDRAL DEFECT MODELFour weeks after the operation, the quality of regenerated
tissues was analyzed by HE staining [Fig. 1(A, aed)], Saf-
ranin-O staining [Fig. 1(A, eeh)], or immunohistochemicalFig. 2. Effects of EP2 agonist on the regeneration of osteochondral defect
after the operation. Each specimen was prepared from control samples (a
k, 80 mg/gel; d, h and l; 400 mg/gel) samples. The quality of regenerated tis
or immunohistochemical staining with anti-type II collagen Ab (iel). Magn
also evaluated with a modiﬁed Wakitani histological scale at 4 (B) and 12
scale for control and contralateral samplesstaining with anti-type II collagen Ab [Fig. 1(A, iel)]. Most
of regenerated tissues in EP2 agonist-treated samples
were Safranin-O-positive and type II collagen-positive,
suggesting the quality as hyaline cartilage. The quality of
regenerated tissue evaluated by modiﬁed Wakitani histo-
logical scale was much better in EP2 agonist-treated
samples than control samples, and the difference was sta-
tistically signiﬁcant in the case of 400 mg/gel-treated sam-
ples [Fig. 1(B): 80 mg, P¼ 0.08; 400 mg, P¼ 0.04]. On the
other hand, there were no statistically signiﬁcant difference
in histological scale between EP2 agonist-treated and
contralateral samples [Fig. 1(B): 80 mg, P¼ 0.21; 400 mg,
P¼ 0.24].
The effect of EP2 agonist treatment was much clear at
12 weeks after operation. In control and contralateral sam-
ples, the amount of regenerated tissues was much less
than that found at 4 weeks after operation, and most of
them were negative for Safranin-O or type II collagen
[Fig. 1(C)]. In EP2 agonist-treated samples, regenerated
tissues reached a considerable width, most of which
were Safranin-O and type II collagen-positive indicating
properties compatible with hyaline cartilage [Fig. 1(C)].
The histological scale of EP2 agonist-treated samples
showed signiﬁcantly better than that of control and also
contralateral samples in the case of 400 mg/gel-treateds. Histological evaluations were performed at 4 (A) or 12 (C) weeks
, e, and i), contralateral (b, f, and j), or EP2 agonist-treated (c, g, and
sues was analyzed by HE staining (aed), Safranin-O staining (eeh),
iﬁcation 2. Bar¼ 2.0 mm. The quality of regenerated tissues was
(D) weeks after the operation. Dotted and open boxes indicate the
, respectively, **P< 0.01; *P< 0.05.
533Osteoarthritis and Cartilage Vol. 17, No. 4samples [Fig. 1(D): vs control, P¼ 0.02; vs contralateral,
P¼ 0.01]. The histological scale of contralateral samples
tended to be better than that of control samples, although
there was no statistical signiﬁcance [Fig. 1(C): 80 mg,
P¼ 0.31; 400 mg; P¼ 0.1, Fig. 1(D): 80 mg, P¼ 0.2;
400 mg; P¼ 0.35].Fig. 3. EP2 agonist promotes proliferation of EP2-positive cells. A: Expres
dral defect model. Specimens were prepared from a normal femur withou
sample (c and g), and an EP2 agonist-treated (400 mg/gel) sample (d and
was performed with anti-EP2 Ab (aed) or anti-PCNA Ab (eeh). Bar¼ 100
itive for PCNA staining were counted under the microscope, and a label
PCNA-positive cells is expressed as the ratio of the labeling index of the E
sample (open bars). The labeling index of control sample relative to thos
were prepared from the chondral defect model at 4 weeks (B), chondral de
(D), and osteochondral defect modeEP2 AGONIST PROMOTED TISSUE REGENERATION IN THE
OSTEOCHONDRAL DEFECT MODELTo analyze the effect of the EP2 agonist on tissue regener-
ation in osteochondral lesions, an osteochondral defect
model was created [Supplementary Fig. 1(CeE)]. At 4 weekssion of EP2 and PCNA in normal and regenerated cartilage of chon-
t any treatment (a and e), a control sample (b and f), a contralateral
h) at 12 weeks after the operation. Immunohistochemical staining
mm. BeE: Quantitative analysis of PCNA-positive cells. Cells pos-
ing index was calculated for each sample. The relative increase in
P2 agonist-treated sample (shaded bars) vs that of the contralateral
e of contralateral sample was indicated in dotted boxes. Samples
fect model at 12 weeks (C), osteochondral defect model at 4 weeks
l for 12 weeks (E), *P< 0.05.
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regenerated tissue in all cases, but therewas a signiﬁcant dif-
ference in histological scale between EP2 agonist-treated
and control samples [Fig. 2(D): 80 mg, P¼ 0.005; 400 mg,
P¼ 0.0003]. As in the chondral defect model, the difference
was not signiﬁcant betweenEP2agonist-treated than contra-
lateral samples [Fig. 2(D): 80 mg,P¼ 0.07; 400 mg,P¼ 0.21].
At 12 weeks after operation, the effect of EP2 agonist
treatment was much evident. The osteochondral defect of
EP2 agonist-treated samples was ﬁlled with Safranin-O
and type II collagen-positive tissues [Fig. 2(C)], and the grad-
ing scale of EP2 agonist-treated samples showed and signif-
icantly better than that of control samples [Fig. 2(D): 80 mg,
P¼ 0.002; 400 mg, P¼ 0.0003] and also than that of contra-
lateral samples in the case of 80 mg/gel-treated samples
[Fig. 2(D): 80 mg, P¼ 0.006; 400 mg, P¼ 0.05]. As we
observed in the chondral defect model, the scale of contralat-
eral samples tended to be better than that of control samples,
and the difference was statistically signiﬁcant in the case of
contralateral sample in 400 mg/gel-treated animals at 12
weeks [Fig. 2(D), P¼ 0.005].EP2 AGONIST STIMULATED THE PROLIFERATION
OF EP2-POSITIVE CELLSIn normal cartilage, almost all cells were EP2-positive as
we previously demonstrated in mice and human articularFig. 4. Effect of EP2 agonist on remodeling of the deep layer zone in cho
lateral sample (a) and EP2 agonist-treated (400 mg/gel) sample (b) of chon
Microscopic view of the osteochondral boundary in the specimens presen
gel) sample. Note that there was no clear boundary, and vascular invasion
whereas a clear tidemark (black arrowhead) was formed in (b). Magniﬁca
teochondral boundary. The boundary formed between articular cartilage a
iﬁed Wakitani scale (0e7, 7 is worse). Samples were prepared from the chcartilage11 [Fig. 3(A, a)]. Almost all cells in regenerated tis-
sues of chondral defect model at 12 weeks after operation
expressed the EP2 receptor in control [Fig. 3(A, b)], contra-
lateral [Fig. 3(A, c)] and EP2-treated samples (400 mg/gel)
[Fig. 3(A, d)]. Identical results were observed in samples
harvested at 12 weeks after operation (data not shown),
suggesting that the cartilage regeneration was conducted
mainly by EP2-positive cells. To evaluate the proliferating
ability of these EP2-positive cells, same specimens were
used for PCNA staining [Fig. 3(A, eeh)]. Almost no cells
were PCNA-positive in normal cartilage [Fig. 3(A, e)] and
control sample [Fig. 3(A, f)], whereas some cells in regener-
ated tissues were PCNA-positive both in contralateral
[Fig. 3(A, g)] and EP2-treated samples [Fig. 3(A, h)]. For
quantitative analysis, we compared relative PCNA-positive
cells as the ratio of the labeling index of the EP2 agonist-
treated sample vs that of the contralateral sample. In the
chondral defect model, the fraction of PCNA-positive cells
in EP2 agonist-treated samples was almost the same as
that in contralateral samples at 4 weeks [Fig. 3(B): 80 mg,
P¼ 0.47; 400 mg, P¼ 0.19]. At 12 weeks, the fraction of
PCNA-positive cells seemed to be higher in EP2 agonist-
treated samples than in contralateral samples, although
the difference was not convincing due to the wide variation
among samples [Fig. 3(C): 80 mg, P¼ 0.04; 400 mg,
P¼ 0.12]. In the osteochondral defect model, the fraction
of PCNA-positive cells in EP2-treated samples was notndral defect model. A: Macroscopic view of specimens from contra-
dral defect model at 12 weeks after the operation. Bar¼ 4.0 mm. B:
ted in (A). (a) Contralateral sample, (b) EP2 agonist-treated (400 mg/
into articular chondrocytes (white arrowhead) was observed in (a),
tion 40. Bar¼ 100 mm. C and D: Quantitative evaluation of the os-
nd subchondral bone was evaluated by category II scale of the mod-
ondral defect model at 4 weeks (C) and at 12 weeks (D), *P< 0.05.
535Osteoarthritis and Cartilage Vol. 17, No. 4different from those in contralateral samples at 4 weeks
[Fig. 3(D): 80 mg, P¼ 0.31; 400 mg, P¼ 0.46], but signiﬁ-
cantly higher at 12 weeks [Fig. 3(E): 80 mg, P¼ 0.02;
400 mg, P¼ 0.02]. In all settings, the labeling index of con-
trol samples showed no difference from those of contralat-
eral samples [Fig. 3(B): P¼ 0.47; Fig. 3(C): P¼ 0.31;
Fig. 3(D): P¼ 0.1; Fig. 3(E): P¼ 0.43].EP2 AGONIST REPAIRED THE OSTEOCHONDRAL BOUNDARYReconstruction of the physiological boundary between ar-
ticular cartilage and underlying bone tissue is important to
maintain the mechanical and biological properties of articu-
lar cartilage. Macroscopical examination of EP2 agonist-
treated (400 mg/gel) samples in chondral defect model at
12 weeks after operation showed a clear boundary between
articular cartilage and subchondral bone [Fig. 4(A, b)].
Microscopical examination demonstrated the reconstruction
of the tidemark [Fig. 4(B, b)]. These ﬁndings were not
observed in contralateral samples. The boundary was not
clear in macroscopical examination [Fig. 4(A, a)], and
microscopical examination also showed no boundary withFig. 5. Effect of EP2 agonist on remodeling of the deep layer zone in os
contralateral sample (a) and EP2 agonist-treated (400 mg/gel) sample (b
Bar¼ 4.0 mm. B: Microscopic view of the osteochondral boundary in the s
(400 mg/gel)-treated sample. Note that there was no clear boundary, and v
observed in (a), whereas a clear tidemark (black arrowhead) was formed i
uation of the osteochondral boundary. The boundary formed between art
scale of the modiﬁed Wakitani scale (0e7, 7 is worse). Samples were p
weeks (D), **Psome vascular structures in the cartilaginous portion
[Fig. 4(B, a)]. The difference was quantitatively evaluated
using the category II scale of the modiﬁed Wakitani scale.
There was no signiﬁcant difference between EP2 agonist-
treated and contralateral samples at 4 weeks [Fig. 4(C)],
but the scale was signiﬁcantly lower in the former than the
latter at 12 weeks after operation [Fig. 4(D): 80 mg,
P¼ 0.03; 400 mg, P¼ 0.04].
Similar ﬁndings were obtained in the osteochondral defect
model (Fig. 5). EP2 agonist-treated (400 mg/gel) samples in
osteochondral defect model at 12 weeks after operation
the showed a clear boundary between articular cartilage
and subchondral bone by macroscopical and microscopical
examinations [Fig. 5(A, b and B, b)], which were not
observed in contralateral samples [Fig. 5(A, a and B, a)].
Quantitative evaluation demonstrated that the boundary
was much better formed in 400 mg/gel-, but not 80 mg/gel-
treated samples than in contralateral samples at 12 weeks
after operation [Fig. 5(D): 80 mg, P¼ 0.07; 400 mg,
P¼ 0.009]. This difference was not observed in samples at
4 weeks [Fig. 5(C)]. These results suggest that the EP2
agonist improved the environment surrounding cartilage.teochondral defect model. A: Macroscopic view of specimens from
) of osteochondral defect model at 12 weeks after the operation.
pecimens presented in (A). (a) Contralateral sample (b) EP2 agonist
ascular invasion into articular chondrocytes (white arrowhead) was
n (b). Magniﬁcation 40. Bar¼ 100 mm. C and D: Quantitative eval-
icular cartilage and subchondral bone was evaluated by category II
repared from the chondral defect model at 4 weeks (C) and at 12
< 0.01.
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SYNOVIUMIt is important whether the EP2 agonist induced unfavor-
able inﬂammation during the regeneration process. We
evaluated the synovium based on mRNA expression and
histological scoring, and also measured the amounts of
cytokines in joint ﬂuid at 4 weeks. PGE2 was reported to
up-regulate the expression of the MMP3, TIMP3, and IL-
1b genes3. The expression of these inﬂammation-related
genes was analyzed by semi-quantitative [Fig. 6(A)] and
quantitative RT-PCR [Fig. 6(B)] using samples taken at 4Fig. 6. EP2 agonist did not induce inﬂammation of the synovium. Inﬂamm
agonist (80 or 400 mg/gel)-treated samples at 4 weeks after the operation
inﬂammatory cytokines of cells in the synovium. RNA extracted from syno
PCR. C: Activity of MMP3 in joint ﬂuid. Joint ﬂuid was collected from knee
ened square) samples, and the activity of MMP3 was analyzed as descri
lyzed in each group. D: Amount of TNF-a and CRP in joint ﬂuid. Joint ﬂuid
synovium in knee joints. Specimens were prepared from a contralateral sa
gel). Magniﬁcation 200. Bar¼ 100 mm. F: Histological scoring of inﬂam
and EP2 agonist-treweeks. No signiﬁcant up-regulation was found in either
gene even in samples treated with a larger amount of
EP2 agonist [Fig. 6(B)]. The activity of MMP3 in joint ﬂuid
had almost the same value as found in untreated joints
[Fig. 6(C)]. The amount of TNF-a or CRP in treated knee
joints showed no signiﬁcant change compared with that in
normal joints either [Fig. 6(D)]. Lining synovial cells showed
no numerical or morphological change on treatment of with
the agonist (400 mg/gel) [Fig. 6(E)], and the histological
scoring for inﬂammation in the treated side was equal to
that in the contralateral side [Fig. 6(F)]. These resultsatory signs in knee joints were investigated in contralateral or EP2
in the osteochondral defect model. A and B: mRNA expression of
vium was analyzed by semi-quantitative (A) and quantitative (B) RT-
joints of contralateral (open square) and EP2 agonist-treated (black-
bed in the Materials and methods section. Five samples were ana-
was collected from ﬁve knee joints in each group. E: HE staining of
mple (a), and EP2 agonist-treated samples (b, 80 mg/gel; c, 400 mg/
mation. Five specimens were analyzed in each of the contralateral
ated groups.
537Osteoarthritis and Cartilage Vol. 17, No. 4indicated that the EP2 agonist induced no signiﬁcant inﬂam-
matory reaction in knee joints at the dose used in this study.
Discussion
PGE2 is a major prostanoid synthesized in response to
various stimuli in a variety of cells and exerts local and sys-
temic pleiotropic effects. In general, PGE2 plays a role in
maintaining the physiological homeostasis, but in some
pathogenic conditions such as inﬂammation and carcino-
genesis, the excess PGE2 induced by factors such as
inﬂammatory cytokines worsens the condition10. From this
standpoint, PGE2 may be regarded as a pro-inﬂammatory
factor promoting the pathological stage of OA. On the other
hand, PGE2 has an anti-inﬂammatory function. Typical anti-
inﬂammatory actions of PGE2 are demonstrated by the sup-
pressive role of the PGE2 signal via EP3 in asthma20. As for
the PGE2 signal via EP2, several reports have analyzed the
relationship with inﬂammation. In human periodontal
ligament cells, PGE2 signal via EP2/EP4 down-regulated
the production of MMP3 and IL-6 stimulated by IL-121,22.
An EP4 agonist stimulated the production of MMP9 in
macrophages, which was not observed on treatment with
an EP2 agonist23. The expression of COX-2 and MMP9
genes was elevated in macrophages from EP2 null
mice24. These results suggested that PGE2 acting through
EP2 has a minimal role as a pro-inﬂammatory factor.
Our previous11 and current study suggested that PGE2
signal via EP2 is not only anti-inﬂammatory but also pro-
motes the regeneration of articular cartilage. The regenera-
tion process of osteochondral defect may mimic the
endochondral ossiﬁcation in fracture healing, and several
studies have already shown that the PGE2 signal involved
in this process25e28, among which signals via EP2 was par-
ticularly important29. Cells derived from bone marrow may
play a central role in this process. On the other hand, the
chondral defect model in this study may mimic the some
stage of OA, in which cartilage tissue disappeared and sub-
chondral bone was sclerosed. At this stage, the recruitment
of bone marrow-derived cells was minimum, and, therefore,
restoration of cartilage tissues was hardly observed. The
therapeutic effects of EP2 agonist in this type of model,
therefore, may be due to its effects directly on the remaining
chondrocytes which are at the resting state in physiological
condition as indicated by no PCNA staining [Fig. 3(A)]. The
effects of EP2 agonist treatment were more prominent at
the later time point (12 weeks) in both chondral and osteo-
chondral defect models, suggesting that the regeneration of
cartilage tissue was dependent on the growth of articular
chondrocytes with low growth property. We observed that
the amount of regenerated tissues was much less at 12
weeks than at 4 weeks after operation in control and contra-
lateral samples, suggesting that regenerated cartilage
tissues may lack the proper quality to maintain the structure,
and the treatment with EP2 agonist may prevent such
degeneration.
One of interesting ﬁnding in the current study is that the
treatment with EP2 agonist enhanced the reconstruction
of boundary between articular cartilage and subchondral
bone, which is an important factor to maintain the articular
structure. We have no clear explanation for this interesting
phenomenon. As mentioned above, EP2 agonists stimulate
the growth of both cartilage and bone marrow cells, which
may relate to the physiological reconstruction of boundary.
It should be noted that the histological scale of contralat-
eral samples tended to be better than that of control
samples (Figs. 1 and 2) and the scales of contralateralsamples of 400 mg/gel-treated animals were signiﬁcantly
better than 80 mg/gel-treated animals at 12 weeks
[Fig. 2(D), P¼ 0.02], suggesting that there might be an ef-
fect from the treated-site through the systemic circulation.
Although there were no signs of a general effect of PGE2
such as a reduction in blood pressure (data not shown),
continuous release of the EP2 agonist may affect tissue re-
generation on the contralateral side.
The ideal regeneration-promoting therapeutics will be
small molecules which can be produced in a large amount,
promote the regeneration of articular cartilage with a physio-
logical structure, and have no adverse effects in other
tissues either locally or systemically. No osteophyte forma-
tion was observed in any samples described in this study
and also samples observed for a longer period (24 weeks)
(data not shown). The results of this study suggested that
the EP2 agonist is a promising candidate for such a new
drug. Because EP4 is not expressed in normal articular
chondrocytes11, we have been focusing the analysis of
EP2 agonist. In the case of osteochondral defect model,
however, the combination of EP2/EP4 agonist is a reason-
able choice to test considering the fact that the simulta-
neous activation of EP2 and EP4 cooperatively induced
type II collagen mRNA expression7. The current experimen-
tal model has been used in several prior investigations of
various articular repair procedures30, but may not reﬂect
the pathogenesis of OA (no mechanical factor, no inﬂam-
mation, no aging factor). Further conﬁrmation of the effect
of EP2 agonists in combination with a more effective drug
delivery system and experimental OA models in larger
animals may lead to a new way to treat OA.Conﬂict of interest
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